Evidence map›Paper›PMID 39506799›Full record

ReviewJournal of nanobiotechnology2024

Organoids and organoid extracellular vesicles-based disease treatment strategies.

Guangyin Zhou, Ruiyang Li, Shihao Sheng, Jingtao Huang, Fengjin Zhou, Yan Wei, Han Liu, Jiacan Su

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Rethinking the microenvironment's role in chemical-induced malignancy.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guangyin Zhou *Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Ruiyang Li *Organoid Research Center, Shanghai University, Shanghai, 200444, China.
Shihao Sheng *Department of Orthopedics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Jingtao Huang *Department of Orthopedics, Shanghai Zhongye Hospital, Shanghai, 200444, China.
Fengjin ZhouDepartment of Orthopaedics, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, 710000, China. xarcsh@164.com.
Yan WeiInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China. ywei@shu.edu.cn.
Han LiuInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China. liuhanqiu@shu.edu.cn.
Jiacan SuInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China. drsujiacan@163.com.

Funding

Integrated Project of Major Research Plan of National Natural Science Foundation of China 92249303Jiangsu Province Natural Science Foundation project BK20241808National Natural Science Foundation of China 82230071Shanghai Committee of Science and Technology Laboratory Animal Research Project 23141900600
6 · The paper itself

Abstract

Organoids are "mini-organs" that self-organize and differentiate from stem cells under in vitro 3D culture conditions, mimicking the spatial structure and function of tissues in vivo. Extracellular vesicles (EVs) are nanoscale phospholipid bilayer vesicles secreted by living cells, rich in bioactive molecules, with excellent biocompatibility and low immunogenicity. Compared to EVs, organoid-derived EVs (OEVs) exhibit higher yield and enhanced biological functions. Organoids possess stem cell characteristics, and OEVs are capable of delivering active substances, making both highly promising for medical applications. In this review, we provide an overview of the fundamental biological principles of organoids and OEVs, and discuss their current applications in disease treatment. We then focus on the differences between OEVs and traditional EVs. Subsequently, we present methods for the engineering modification of OEVs. Finally, we critically summarize the advantages and challenges of organoids and OEVs. In conclusion, we believe that a deeper understanding of organoids and OEVs will provide innovative solutions to complex diseases.

Indexed as

Extracellular VesiclesOrganoidsAnimalsDrug Delivery SystemsHumansStem CellsDisease treatmentEngineering modificationExtracellular vesiclesOrganoidsOrganoids extracellular vesicles

Identifiers

PMID39506799
PMCPMC11542470

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.